Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Chardan Capital cut their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Up 7.8 %

Femasys stock traded up $0.09 during trading hours on Tuesday, hitting $1.25. The stock had a trading volume of 527,125 shares, compared to its average volume of 196,673. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $28.63 million, a P/E ratio of -1.54 and a beta of -2.81. Femasys has a 12-month low of $0.86 and a 12-month high of $2.40. The stock’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.12.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts anticipate that Femasys will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of Femasys in the fourth quarter worth about $25,000. Aljian Capital Management LLC bought a new position in Femasys during the 3rd quarter worth about $27,000. XTX Topco Ltd grew its holdings in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after acquiring an additional 17,473 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.